GGrantIndex
Sort

261,768 grants matching gene therapy

Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves

$998,309
Yogen Saunthararajah · University Of Michigan At Ann Arbor · P01 · FY2019 · HL

Gene Therapy for Urea Cycle Disorders

$998,305
James M Wilson · University Of Pennsylvania · P01 · FY2010 · HD

Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk

$998,304
Ellen L. Goode · Mayo Clinic Rochester · R01 · FY2022 · CA

Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection

$998,266
Priscilla Y. Hsue · University Of California, San Francisco · R01 · FY2010 · HL

Novel mechanisms of NSAID action in Alzheimer disease

$998,120
University Of California San Diego · P01 · FY2002 · AG

Protecting Pancreatic Islet Grafts from Rejection

$998,068
Uwe D. Staerz · Isogenis, Inc. · R44 · FY2008 · DK

A Haplotype Map for Multiple Sclerosis

$997,968
Stephen L Hauser · University Of California, San Francisco · R01 · FY2013 · NS

Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe

$997,899
Wu-Bo Li · Functional Genetics, Inc. · R44 · FY2012 · AI

Novel small-molecule therapies for CF

$997,891
Alan S Verkman · University Of California, San Francisco · P30 · FY2007 · DK

Role of Viral Reservoirs in the Pathogenesis of HIV Disease

$997,850
Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

Mechanisms of neocortical and sensory hyperexcitability in Fragile X Syndrome

$997,830
Kimberly M Huber · Ut Southwestern Medical Center · U54 · FY2019 · HD

Automated Systems for Detection and Molecular Characterization of Circulating Tum

$997,818
Yuling Luo · Advanced Cell Diagnostics, Inc. · R44 · FY2010 · CA

The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations

$997,800
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2025 · CA

The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations

$997,800
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2023 · CA

Novel Vaginal Microbicides Based On Stable AAV-Neutralizing Antibody Gene Transfe

$997,779
Wayne A. Marasco · Dana-Farber Cancer Inst · R33 · FY2010 · AI

Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)

$997,731
Paul B Rosenberg · Johns Hopkins University · R01 · FY2020 · AG

Medical Retina Fellowship

$997,688
Catherine Cukras · National Eye Institute · ZIE · FY2022 · EY

Rapid, Multiplexed Biosensor for Non-Invasive Detection of Gene Mutations and Personalization of Therapy in Non-Small Cell Lung Cancer

$997,685
Avni A Argun · Giner, Inc. · R44 · FY2023 · CA

Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.

$997,658
Michael King Schultz · Viewpoint Molecular Targeting, Inc. · R44 · FY2020 · CA

Characterization of CAR-directed T-cells to suppress HIV-1 in vivo

$997,645
Scott G Kitchen · University Of California Los Angeles · U19 · FY2016 · AI

Development of TP-317 in Ulcerative Colitis

$997,635
John Parkinson · Thetis Pharmaceuticals, Llc · R44 · FY2023 · DK

Antibody-Biocide Fusions to Control Cryptosporidium

$997,510
Michael Imboden · Iogenetics, Llc · R44 · FY2009 · AI

Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer

$997,501
Alex Toker · Beth Israel Deaconess Medical Center · R35 · FY2024 · CA

Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies

$997,500
Wenyi Wei · Beth Israel Deaconess Medical Center · R35 · FY2024 · CA

Precision microRNA medicine in cancer

$997,500
Frank J. Slack · Beth Israel Deaconess Medical Center · R35 · FY2024 · CA